跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 3 天前AI 评分45

罗氏口服SERD抑制剂giredestrant获FDA批准用于晚期乳腺癌

Roche enters the SERD market with FDA approval in late-stage breast cancer

AI 导读

罗氏(Roche)口服选择性雌激素受体降解剂(SERD)giredestrant获美国FDA批准,用于晚期乳腺癌治疗。该药曾处于等待两个不同FDA审批决定的特殊状态。

正文

Roche’s big-hope breast can­cer pill giredestrant was in an odd sit­u­a­tion in that it was await­ing two dif­fer­ent FDA ap­proval de­ci­sions. Al­so odd­ly, the sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news